Pfizer Inc. (NYSE:PFE) Shares Acquired by Garland Capital Management Inc.

Share on StockTwits

Garland Capital Management Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 136.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 346,873 shares of the biopharmaceutical company’s stock after purchasing an additional 200,273 shares during the quarter. Pfizer comprises about 4.8% of Garland Capital Management Inc.’s portfolio, making the stock its 6th biggest holding. Garland Capital Management Inc.’s holdings in Pfizer were worth $12,730,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. NewSquare Capital LLC lifted its holdings in shares of Pfizer by 0.4% in the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock valued at $1,976,000 after purchasing an additional 266 shares in the last quarter. Northwest Wealth Management LLC increased its position in shares of Pfizer by 2.4% during the third quarter. Northwest Wealth Management LLC now owns 11,311 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 268 shares during the last quarter. Aevitas Wealth Management Inc. increased its position in shares of Pfizer by 1.7% during the second quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock valued at $520,000 after acquiring an additional 269 shares during the last quarter. Cutter & CO Brokerage Inc. increased its position in shares of Pfizer by 2.0% during the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 274 shares during the last quarter. Finally, Beaumont Asset Management L.L.C. increased its position in shares of Pfizer by 1.3% during the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock valued at $694,000 after acquiring an additional 276 shares during the last quarter. 69.08% of the stock is owned by institutional investors and hedge funds.

NYSE:PFE traded up $0.75 during trading hours on Friday, hitting $38.18. 28,992,325 shares of the company’s stock traded hands, compared to its average volume of 20,809,482. The firm has a market cap of $212.16 billion, a P/E ratio of 15.15, a P/E/G ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97. The business’s fifty day simple moving average is $36.59 and its two-hundred day simple moving average is $36.49. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The company had revenue of $11.80 billion during the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company earned $0.80 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.84 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 3.98%. The ex-dividend date is Thursday, November 5th. Pfizer’s dividend payout ratio is 51.53%.

In other Pfizer news, Director Ronald E. Blaylock acquired 13,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now owns 4,000 shares of the company’s stock, valued at $154,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.08% of the stock is currently owned by company insiders.

PFE has been the subject of a number of recent research reports. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Royal Bank of Canada set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Friday, October 16th. UBS Group raised their target price on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Berenberg Bank initiated coverage on Pfizer in a research report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 target price for the company. Finally, Atlantic Securities downgraded Pfizer from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $44.00 to $39.00 in a research report on Monday, October 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $39.81.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is the float in trading stocks?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.